Virios therapeutics announces scheduling of fda meeting in march 2023 to discuss imc-1 fibromyalgia phase 3 program

Atlanta, jan. 05, 2023 (globe newswire) --  virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“fm”), announced today that its end-of-phase 2 meeting request with the u.s. food and drug administration (“fda”) to discuss advancing imc-1 into phase 3 development as a treatment for fm has been scheduled for mid-march 2023. at this meeting, the company will discuss with the fda plans for a phase 3 program that would support submission of a new drug application for imc-1 for the treatment of fm. the company plans to provide a program update by the end of april following the receipt of formal written feedback from the fda.
VIRI Ratings Summary
VIRI Quant Ranking